Intelligence Feed event · Equity · 2026-10-04

    Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS

    Question

    Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS

    Direct answer

    The Phase 2 RAINFOL-01 trial results address a high unmet need in platinum-resistant ovarian cancer, where historical response rates for standard-of-care chemotherapy remain subdued. With a median duration of response exceeding 12 months, the Rina-S antibody-drug conjugate (ADC) program strengthens Genmab's wholly-owned clinical pipeline value independent of partnered royalty streams.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-phase-2-ovarian-cancer-trial-demonstrates-45-9-orr-and-9-5m-median-pfs-b00ad3

    EQUITY
    Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS
    The Phase 2 RAINFOL-01 trial results address a high unmet need in platinum-resistant ovarian cancer, where historical response rates for standard-of-care chemotherapy remain subdued. With a median duration of response exceeding 12 months, the Rina-S antibody-drug conjugate (ADC) program strengthens Genmab's wholly-owned clinical pipeline value independent of partnered royalty streams.
    GMAB
    Impact
    75
    OCT 4
    SIG
    90%
    GMAB
    Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS
    The Phase 2 RAINFOL-01 trial results address a high unmet need in platinum-resistant ovarian cancer, where historical response rates for standard-of-care chemotherapy remain subdued. With a median duration of response exceeding 12 months, the Rina-S antibody-drug conjugate (ADC) program strengthens Genmab's wholly-owned clinical pipeline value independent of partnered royalty streams.
    → A 45.9% ORR in platinum-resistant ovarian cancer de-risks Phase 3 clinical development and potential commercial peak sales value for GMAB's ADC pipeline.
    Impact
    The Phase 2 RAINFOL-01 trial results address a high unmet need in platinum-resistant ovarian cancer, where historical response rates for standard-of-care chemotherapy remain subdued. With a median duration of response exceeding 12 months, the Rina-S antibody-drug conjugate (ADC) program strengthens Genmab's wholly-owned clinical pipeline value independent of partnered royalty streams.
    Affected
    GMAB
    Transmission
    A 45.9% ORR in platinum-resistant ovarian cancer de-risks Phase 3 clinical development and potential commercial peak sales value for GMAB's ADC pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABclinical pipeline de-risking boosting ADC portfolio NPVUp1-4wPhase 2 trial shows 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month